Capstone Holding

Capstone Holding EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Capstone Holding (CAPS) as of Nov 1, 2026 is -3.58 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -638,000.00 USD — a change of 461.60% (lower).

EBITDA

-3.58 MUSD

YoY

461.60%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Capstone Holding is 2025 -3.58 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Capstone Holding was 2024 -638,000.00 USD. It decreases by 461.60% lower compared to the previous year.

The Capstone Holding EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-397,000.00 USD
Jan 1, 2019
-723,000.00 USD
Jan 1, 2020
2.40 M USD
Jan 1, 2021
4.64 M USD
Jan 1, 2022
3.99 M USD
Jan 1, 2023
-2.06 M USD
Jan 1, 2024
-638,000.00 USD
Jan 1, 2025
-3.58 M USD
The Capstone Holding EBITDA history
YEAREBITDAYoY
-3.58 MUSD+461.60%
-638,000.00USD-68.97%
-2.06 MUSD-151.49%
3.99 MUSD-13.87%
4.64 MUSD+93.49%
2.40 MUSD-431.40%
-723,000.00USD+82.12%
-397,000.00USD-76.37%
-1.68 MUSD+6.06%
-1.58 MUSD-46.10%
-2.94 MUSD-35.04%
-4.52 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Capstone Holding Stock analysis

What does Capstone Holding do? Capstone Therapeutics Corp. is a biopharmaceutical company focused on the development of innovative therapeutic solutions for unmet medical needs. The company was founded in 1987 and is headquartered in Tempe, Arizona. It began as a research project at Arizona State University, eventually leading to the founding of the company. Capstone Therapeutics utilizes its technology platform in peptide chemistry, cell biology, and pharmacology to develop therapies for diseases with limited treatment options. Its core business includes developing medications for neurodegenerative diseases like Alzheimer's and oncological diseases with no effective treatment options. The company collaborates with other industry leaders in biotechnology and holds a strong intellectual property position. Capstone Therapeutics aims to improve the lives of individuals with serious illnesses through its innovative products and strategic approach. Capstone Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Capstone Holding stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Capstone Holding is -3.58 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Capstone Holding changed from -638,000.00 USD to -3.58 M USD, representing a 461.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Capstone Holding since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Capstone Holding historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Capstone Holding

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Capstone Holding